Cognitive Assessment Battery (CAB) Beta Study

Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases

NCT02288000 ·Status: TERMINATED ·Phase: PHASE1

Brain Imaging and Mental Disorders of Aging Intervention

NCT00267163 ·Status: COMPLETED ·Phase: PHASE4

Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

NCT00675090 ·Status: COMPLETED ·Phase: PHASE1

Daridorexant for Alzheimer Disease Prevention

NCT07213349 ·Status: RECRUITING ·Phase: PHASE2

Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)

NCT02064920 ·Status: COMPLETED ·Phase: PHASE2

Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type

NCT03721705 ·Status: COMPLETED ·Phase: PHASE3

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

NCT02406027 ·Status: TERMINATED ·Phase: PHASE2

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

NCT04971733 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease

NCT00955422 ·Status: COMPLETED

A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease

NCT00736775 ·Status: COMPLETED ·Phase: PHASE1

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

NCT00293176 ·Status: COMPLETED ·Phase: PHASE4

Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment

NCT05289804 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of CST-2032 in Subjects With Cognitive Impairment

NCT05033912 ·Status: WITHDRAWN ·Phase: PHASE1

Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development

NCT01487395 ·Status: COMPLETED ·Phase: PHASE1

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

NCT00149175 ·Status: COMPLETED

An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease

NCT07153848 ·Status: RECRUITING

Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease

NCT02899091 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

NCT00297362 ·Status: COMPLETED

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

NCT05161715 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

NCT01602393 ·Status: COMPLETED ·Phase: PHASE2

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

NCT00240695 ·Status: COMPLETED ·Phase: PHASE3

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

NCT00935493 ·Status: COMPLETED ·Phase: NA

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

NCT00236431 ·Status: COMPLETED ·Phase: PHASE3

A Study of Gantenerumab in Participants With Mild Alzheimer Disease

NCT02051608 ·Status: COMPLETED ·Phase: PHASE3